EXELIXIS, INC.
EXEL evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $13.93B
- Lead Asset:
- COMETRIQ (Approved)
What it means
What to watch
Prepared research question
What matters most for EXEL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EXEL
Exelixis, Inc. (EXEL) is a biopharmaceutical company focused on developing and commercializing oral kinase inhibitors, anchored by its approved product CABOMETYX (cabozantinib) and advancing the investigational agent zanzalintinib across multiple oncology indications.
Key risk: Patent expirations for cabozantinib
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jul 3, 2026.
Tracking 4 pipeline candidates · 13 clinical trials · 4 catalysts · 2 FDA decisions for EXELIXIS, INC..
Exelixis, Inc. (EXEL) is a biopharmaceutical company focused on developing and commercializing oral kinase inhibitors, anchored by its approved product CABOMETYX (cabozantinib) and advancing the investigational agent zanzalintinib across multiple oncology indications.
- Cash & equivalents of $281.4M and shareholders' equity of $1,843.8M as of 2026-07-03 [sec].
- CABOMETYX (cabozantinib) is approved for advanced melanoma and is being expanded into renal cell carcinoma and neuroendocrine tumors [news · published 2026-09-14].
- Zanzalintinib (XL092) is in Phase 3 trials for metastatic colorectal cancer, non-clear cell renal cell carcinoma, and pancreatic neuroendocrine tumors [catalyst].
- A Phase 2 trial of zanzalintinib in combination with pembrolizumab for first-line maintenance in metastatic squamous non-small cell lung cancer is set to start on 2026-12-15 [catalyst].
- Exelixis plans a potential launch of zanzalintinib in colorectal cancer later in 2026 [news · published 2026-09-15].
What works
- CABOMETYX showed significant improvement in progression-free survival versus placebo in a subgroup analysis of the Phase 3 CABINET trial for neuroendocrine tumors [news · published 2026-05-30].
- Exelixis has a deep pipeline with multiple Phase 3 studies for zanzalintinib across different tumor types, indicating a broad development strategy [catalyst].
- The company reported a strong Q1 2026 with EPS of $0.87, beating estimates [news · published 2026-05-05].
What to weigh
- Exelixis faces patent expirations for cabozantinib s-malate starting in 2032-02-10 and 2033-07-09, which could impact future revenue [catalyst].
- The competitive landscape for zanzalintinib includes established players like AstraZeneca and Nektar Therapeutics in Phase 1/2 trials [pipeline].
- The company's growth strategy relies heavily on the successful launch and adoption of zanzalintinib, which is still investigational and not yet approved [news · published 2026-09-15].
From the filings
Quoted directly from source documents.
CABOMETYX PFS benefit in NET subgroup analysis
“CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status”
News · May 30, 2026
Zanzalintinib Phase 3 start for metastatic colorectal cancer
“Phase3_Start: A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer”
Catalysts · September 7, 2022
Exelixis plans zanzalintinib launch in colorectal cancer
“Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year”
News · September 15, 2026
Catalyst timeline
- 2026-12-15 · Phase2_Start — Phase2_Start: A Phase 2, Single-Arm, Multicenter Trial of Zanzalintinib in Combination With Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer — This trial initiation will test zanzalintinib in a new indication, potentially expanding its pipeline.
- 2032-02-10 · Patent_Expiry · CABOZANTINIB S-MALATE — Patent_Expiry: NDA203756 — Patent expiry for cabozantinib s-malate could allow generic competition, affecting revenue.
- 2033-07-09 · Patent_Expiry · CABOZANTINIB S-MALATE — Patent_Expiry: NDA208692 — Another patent expiry for cabozantinib s-malate, further opening to generics.
- 2036-06-30 · Patent_Expiry · COBIMETINIB FUMARATE — Patent_Expiry: NDA206192 — Patent expiry for cobimetinib fumarate, which may impact partnered product revenue.
Risks & what to watch (3)›
Key risks
- Patent expirations for cabozantinib — Cabozantinib s-malate patents expire in 2032 and 2033, potentially opening to generic competition [catalyst].
- Zanzalintinib regulatory uncertainty — Zanzalintinib is still investigational; NDA decision expected by December 2026, with no guarantee of approval [news · published 2026-05-05].
- Competitive pressure in pipeline — Zanzalintinib faces competition from AstraZeneca and Nektar Therapeutics in Phase 1/2 trials [pipeline].
What to watch
- FDA decision on zanzalintinib NDA expected by December 2026 [news · published 2026-05-05].
- Phase 2 start of zanzalintinib + pembrolizumab in NSCLC on 2026-12-15 [catalyst].
- Continued expansion of CABOMETYX into neuroendocrine tumors following positive CABINET trial results [news · published 2026-05-30].
- Potential launch of zanzalintinib in colorectal cancer later in 2026 [news · published 2026-09-15].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run EXELIXIS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available EXELIXIS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.35
Lead: Approved
4 candidates
4 upcoming, next in ~62d
0 buys · 10 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
691
Total value held
$10.46B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 30,816,309 | $1.32B |
| renaissance technologies llc | 13,726,993 | $588.8M |
| farallon capital management llc | 13,111,010 | $562.3M |
| aqr capital management llc | 13,095,741 | $561.7M |
| vanguard portfolio management llc | 12,085,273 | $518.3M |
| vanguard capital management llc | 11,258,984 | $482.9M |
| state street corp | 10,298,439 | $441.7M |
| fuller & thaler asset management, inc. | 8,542,236 | $366.4M |
| geode capital management, llc | 7,795,610 | $334.4M |
| arrowstreet capital, limited partnership | 4,834,625 | $207.4M |
Showing top 10 of 691 institutional holders of EXELIXIS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 16.2%
- Days to cover
- 13.1
- Shares short
- 30,010,146
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EXEL short interestGovernance
Frequently asked questions
What is the AI investment thesis for EXELIXIS, INC.?
Exelixis, Inc. (EXEL) is a biopharmaceutical company focused on developing and commercializing oral kinase inhibitors, anchored by its approved product CABOMETYX (cabozantinib) and advancing the investigational agent zanzalintinib across multiple oncology indications.
What is EXELIXIS, INC.'s lead drug candidate?
EXELIXIS, INC.'s most advanced tracked candidate is COMETRIQ (Approved) for Progressive, metastatic medullary thyroid cancer (MTC).
What is EXELIXIS, INC.'s next catalyst?
EXELIXIS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Phase 2, Single-Arm, Multicenter Trial of Zanzalintinib in Combination With Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer" — expected December 15, 2026.
Who is the CEO of EXELIXIS, INC.?
Dr. Michael M. Morrissey Ph.D. is the chief executive officer of EXELIXIS, INC. (EXEL).
Where is EXELIXIS, INC. headquartered?
EXELIXIS, INC. (EXEL) is headquartered in Alameda, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.